

[Supplementary online-only material for Brown TR, Slee A: Randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis. *Int J MS Care*. 2015;17(2):83–89.]

Supplementary Table 1. Change from baseline to week 6 in primary and secondary endpoints

| Population ^a | Duloxetine | | Placebo | | P value ^b |
|---|------------|---------------|---------|---------------|----------------------|
| | n | Mean (SD) | n | Mean (SD) | |
| Percent change in worst pain score | | | | | |
| Per-protocol | 14 | -29.1 (20.41) | 18 | -11.5 (18.18) | .016 ^c |
| ITT observed (complete cases) | 14 | -29.1 (20.41) | 19 | -10.9 (17.87) | .011 ^c |
| ITT - missing imputed as placebo mean (-10.9) | 18 | -25.0 (19.46) | 20 | -10.9 (17.39) | .024 ^c |
| ITT - missing imputed as worst observed (+40.1) | 18 | -13.7 (34.54) | 20 | -8.38 (20.80) | .564 |
| ITT reduction in worst pain >30% - missing imputed as no reduction >30% - No. (%) | | 6 (33.3) | | 2 (10.0) | .117 |
| Percent change in average pain score | | | | | |
| Per-protocol | 14 | -38.5 (29.10) | 18 | -10.4 (18.85) | .002 ^c |
| ITT observed (complete cases) | 14 | -38.5 (29.10) | 19 | -9.84 (18.47) | .002 ^c |
| ITT - missing imputed as placebo mean (-9.8) | 17 | -33.4 (28.55) | 20 | -9.84 (17.98) | .004 ^c |
| ITT - missing imputed as worst observed (+19.9) | 17 | -28.2 (34.86) | 20 | -8.35 (19.17) | .035 ^c |
| ITT reduction in average pain >30% - missing imputed as no reduction >30% - No. (%) | 10 | 8 (44.4) | 19 | 1 (5.0) | .007 ^c |
| Change in sleep score | | | | | |
| Per-protocol | 13 | -0.86 (1.61) | 18 | -0.64 (1.11) | .657 |
| ITT observed (complete cases) | 13 | -0.86 (1.61) | 19 | -0.67 (1.09) | .688 |
| Change in number of rescue medications | | | | | |
| Per-protocol | 13 | -1.85 (3.43) | 17 | -0.67 (2.22) | .263 |
| ITT observed (complete cases) | 13 | -1.85 (3.43) | 18 | -0.68 (2.16) | .253 |
| Change in Beck Depression Inventory | | | | | |
| Per-protocol | 14 | -2.07 (5.28) | 18 | -3.00 (4.61) | .600 |
| ITT observed (complete cases) | 16 | -1.56 (5.32) | 20 | -2.10 (5.42) | .767 |
| Change in SF-36 physical component score | | | | | |
| Per-protocol | 13 | 0.84 (5.77) | 18 | 0.06 (5.19) | .697 |
| ITT observed (complete cases) | 15 | 0.74 (5.65) | 20 | 0.22 (4.94) | .774 |

| | | | | | |
|--|----|-------------|----|-------------|------|
| Change in SF-36 mental component score | | | | | |
| Per-protocol | 13 | 3.51 (9.26) | 18 | 2.44 (7.90) | .731 |
| ITT observed (complete cases) | 15 | 3.39 (8.69) | 20 | 2.18 (7.52) | .664 |
| Subject global impression week 6 | | | | | |
| Per-protocol | 13 | 4.77 (1.30) | 18 | 3.94 (1.16) | .074 |
| ITT observed (complete cases) | 15 | 4.53 (1.55) | 20 | 3.70 (1.34) | .098 |

Abbreviation: ITT, intention-to-treat.

^aPer-protocol population is subjects who completed the study per protocol through primary endpoint at week 6. ITT population includes all randomized patients.

^bP values are from the *t* test for independent samples for continuous variables and the Fisher exact test for categorical variables.

^cStatistically significant value.